Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...
New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...
Paris, October 11, 2024. Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.
Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...
Paul Hudson is reshaping Sanofi into a modern healthcare company with the ambition to transform the practice of medicine. Paul and the Sanofi teams are focusing efforts to discover, develop, ...
If you are a healthcare professional or a patient seeking to report an adverse event, please call 1-800-265-7927 to speak with a Sanofi Medical Information agent or click here to visit Sanofi Medical ...
John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of ...
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is ...
Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved ...
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...
Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this ...